{"product_id":"cbl-antibody-casitas-b-lineage-lymphoma-proto-oncogene-bha17128526","title":"CBL Antibody \/ Casitas B-lineage lymphoma proto-oncogene","description":"\u003ch2\u003eOverview\u003c\/h2\u003e \u003cp\u003eCBL Antibody \/ Casitas B-lineage lymphoma proto-oncogene is an antibody targeting \u003cstrong\u003eCBL\u003c\/strong\u003e, raised in \u003cstrong\u003eRabbit\u003c\/strong\u003e for protein detection and localization studies where these specifications are required.\u003c\/p\u003e \u003ch2\u003eKey elements and design rationale\u003c\/h2\u003e \u003cul\u003e \u003cli\u003e\n\u003cstrong\u003eTarget:\u003c\/strong\u003e CBL (reported localization: Cell surface, cytoplasmic).\u003c\/li\u003e \u003cli\u003e\n\u003cstrong\u003eAntibody identity:\u003c\/strong\u003e Polyclonal (rabbit origin); Rabbit IgG.\u003c\/li\u003e \u003cli\u003e\n\u003cstrong\u003eConjugate\/label:\u003c\/strong\u003e Unconjugated (affects detection chemistry and multiplex compatibility).\u003c\/li\u003e \u003cli\u003e\n\u003cstrong\u003eFormat:\u003c\/strong\u003e Antigen affinity purified.\u003c\/li\u003e \u003cli\u003e\n\u003cstrong\u003eSpecies reactivity:\u003c\/strong\u003e Human, Mouse, Rat.\u003c\/li\u003e \u003cli\u003e\n\u003cstrong\u003eListed applications:\u003c\/strong\u003e WB, IHC-P, FACS, Direct ELISA (refer to on-page specifications for application-specific guidance).\u003c\/li\u003e \u003c\/ul\u003e  \u003ch2\u003eBiological background\u003c\/h2\u003e \u003cp\u003eCBL (Cbl proto-oncogene) is also known as C-CBL, RNF55, CBL2 and E3 ubiquitin-protein ligase CBL. CBL is mapped to chromosome 11q23.3-qter by molecular characterization of the breakpoints in 2 somatic cell hybrids. The encoded protein is one of the enzymes required for targeting substrates for degradation by the proteasome. This protein mediates the transfer of ubiquitin from ubiquitin conjugating enzymes(E2) to specific substrates. This protein also contains an N-terminal phosphotyrosine binding domain that allows it to interact with numerous tyrosine-phosphorylated substrates and target them for proteasome degradation. As such it functions as a negative regulator of many signal transduction pathways. This gene has been found to be mutated or translocated in many cancers including acute myeloid leukaemia. Mutations in this gene are also the cause of Noonan syndrome-like disorder.\u003c\/p\u003e \u003ch2\u003eResearch relevance and current trends\u003c\/h2\u003e \u003cul\u003e \u003cli\u003eComparative expression profiling across cell types, tissues, or perturbations (e.g., drug treatment, genetic editing, or differentiation).\u003c\/li\u003e \u003cli\u003eSubcellular localization and trafficking studies, including co-localization with pathway markers in microscopy-based assays.\u003c\/li\u003e \u003cli\u003eIntegration of protein-level measurements with transcriptomics or proteomics to relate abundance to regulation and phenotype.\u003c\/li\u003e \u003c\/ul\u003e \u003ch2\u003eCommon research applications\u003c\/h2\u003e \u003cul\u003e \u003cli\u003eWestern blotting: researchers commonly compare relative signal levels across conditions and use appropriate negative\/positive controls for interpretation.\u003c\/li\u003e \u003cli\u003eImmunohistochemistry: researchers commonly compare relative signal levels across conditions and use appropriate negative\/positive controls for interpretation.\u003c\/li\u003e \u003cli\u003eFlow cytometry: researchers commonly compare relative signal levels across conditions and use appropriate negative\/positive controls for interpretation.\u003c\/li\u003e \u003cli\u003eELISA: researchers commonly compare relative signal levels across conditions and use appropriate negative\/positive controls for interpretation.\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003eInterpretation should account for antibody-dependent factors such as epitope accessibility, isoforms, and sample preparation differences across workflows.\u003c\/p\u003e \u003ch2\u003eNotes for experimental interpretation\u003c\/h2\u003e \u003cul\u003e \u003cli\u003e\n\u003cstrong\u003eIsoforms and PTMs:\u003c\/strong\u003e many targets have multiple isoforms and post-translational modifications that can shift apparent signal or localization; interpret bands\/signals accordingly.\u003c\/li\u003e \u003cli\u003e\n\u003cstrong\u003eEpitope context:\u003c\/strong\u003e binding can depend on protein conformation and sample processing; region information in the title\/immunogen can help anticipate what may be detected.\u003c\/li\u003e \u003cli\u003e\n\u003cstrong\u003eSpecies differences:\u003c\/strong\u003e predicted or validated reactivity may vary by ortholog sequence and sample context; confirm in your model system.\u003c\/li\u003e \u003cli\u003e\n\u003cstrong\u003eControl concepts:\u003c\/strong\u003e include negative controls (no-primary\/isotype), and where possible genetic controls (KO\/KD) or independent antibodies to strengthen conclusions.\u003c\/li\u003e \u003c\/ul\u003e \u003c!-- Sources (internal): - UniProtKB entry P22681 — UniProt — https:\/\/www.uniprot.org\/uniprotkb\/P22681 - Gene search: CBL — NCBI Gene — https:\/\/www.ncbi.nlm.nih.gov\/gene\/?term=CBL - Ensembl search: CBL — Ensembl — https:\/\/www.ensembl.org\/Multi\/Search\/Results?q=CBL - PubMed search: CBL antibody — PubMed — https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=CBL+antibody - Reactome search: CBL — Reactome — https:\/\/reactome.org\/content\/query?q=CBL --\u003e","brand":"NSJ Bioreagents","offers":[{"title":"0.5mg\/ml if reconstituted with 0.2ml sterile DI water \/ 100 ug","offer_id":53046424338797,"sku":"RQ6954","price":449.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/get_image_106a846f-5923-4ed4-a68c-4fa297f1303f.jpg?v=1772000548","url":"https:\/\/www.ebiohippo.com\/products\/cbl-antibody-casitas-b-lineage-lymphoma-proto-oncogene-bha17128526","provider":"BioHippo","version":"1.0","type":"link"}